Luis E. Rodriguez

General Practice

Guaynabo, PR 00969

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.

ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.

Journal: Molecular cancer therapeutics

Published: December 01, 2022

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.

Journal: BMC cancer

Published: November 21, 2020

Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.

Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.

Journal: Protein & cell

Published: January 30, 2017

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Journal: Molecular cancer research : MCR

Published: April 28, 2015

Showing 1-4 of 4

Last Updated: 09/26/2026